BioPharma, Pharma Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds By Frank Vinluan
BioPharma, Pharma Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior By Frank Vinluan
BioPharma, Pharma Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss By Frank Vinluan
BioPharma, Pharma New Novo Nordisk Ozempic Data Build Case for Adding Kidney Disease to Label By Frank Vinluan
BioPharma, Pharma Novo Nordisk Strikes Deal for Late-Stage Hypertension & Kidney Disease Drug By Frank Vinluan
BioPharma, Pharma Novo Nordisk’s Star Diabetes & Obesity Drug Shows Promise in Kidney Disease By Frank Vinluan
Artificial Intelligence, Pharma, BioPharma Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D By Frank Vinluan
BioPharma, Pharma Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal By Frank Vinluan
BioPharma, Pharma Novo Nordisk Aims to Succeed Where Sanofi Faltered Drugging a Weight-Loss Target By Frank Vinluan
BioPharma, Pharma Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks By Frank Vinluan
BioPharma, Pharma Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75% By Frank Vinluan
BioPharma, Pharma Novo Nordisk’s Diabetes Pill Rybelsus Gets FDA O.K. as First-Line Therapy By Frank Vinluan
BioPharma, Pharma, Legal Claiming Insulin Price Conspiracy, CA Sues Lilly, Novo Nordisk, Sanofi & PBMs By Frank Vinluan
BioPharma, Pharma Amgen Weighs In to Chase Rival Obesity Drugs From Novo Nordisk and Eli Lilly By Frank Vinluan
